Marinomed has already achieved many milestones in its short history. The selected scientific publications and press releases provide information on the most important events to date.
February 19, 2021
Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19
July 16, 2020
Marinomed Biotech AG: Carragelose® effective against SARS-CoV-2 in cell culture assays
January 22, 2020
Marinomed Biotech AG: Sellers complete accelerated bookbuilding; 105,000 Marinomed shares have been sold for EUR 95 per share
January 22, 2020
Marinomed Biotech AG: Shareholders offer shares by way of an accelerated bookbuilding
October 16, 2019
Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG sold Marinomed shares by way of an accelerated bookbuilding for EUR 95 per share to institutional investors
October 15, 2019
Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG start partial sale of Marinomed shares by way of an accelerated bookbuilding
April 23, 2019
Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
February 28, 2019
Marinomed Biotech AG: Greenshoe option fully exercised
January 29, 2019
Marinomed sets offer price at 75 Euro per share
January 29, 2019
Marinomed announces strong investor demand and expected offer price
January 23, 2019
Marinomed resumes offer period of the IPO
November 29, 2018
Marinomed suspends offer period of the current IPO
November 16, 2018
Marinomed determines IPO timeline and terms
November 05, 2018